

Accelerating Health Equity *One Patient at a Time*

2025 ANNUAL REPORT





Table of Contents

Letter from CEO & Board Chair	3
2025 Global Impact	5
Treat	9
Amplify	11
Sustain	13
Financials	15
Donors & Supporters	16


Our Mission & Vision

Our mission is to accelerate health equity.

We do this by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those whom no one else is helping.

Our vision is a world where all people can access high-impact medicines,

where geography is not destiny, and where everyone can strive for health with dignity and hope.





Letter from the CEO & Board Chair

In 2022, we drew a defining line in the sand with the launch of our five-year Equity in Action strategic plan. We committed to doubling the number of new patients, the number of diseases we supported, and the number of partners in our Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT). Our human-centered strategy is anchored in a single, steadfast principle that defines our work: health equity is a universal right. Advancing it demands urgency, bold innovation, and a commitment to ensuring geography never determines destiny.

With nearly 5,000 new patients enrolled in 2025 – and for the first time surpassing 40,000 patients treated in a single year – we are firmly on track to meet our goals. Our sustained growth, both among newly

diagnosed patients and patients continuing treatment from the prior year, reflects our expanding reach into low- and middle-income countries, regions that bear nearly two-thirds of the world's 10 million annual cancer deaths.

We now provide access to 17 high-impact therapies across 15 cancers and other critical diseases, broadening access to innovation for patients. Our proven Max Access Solutions model is providing treatment in collaboration with local physicians and institutions in seven new countries since 2022, advancing toward our goal of reaching 10 by 2026. Our Humanitarian PACT expansion in 2025 to nine partners marks another pivotal step toward our partnership goals. These partners, whose staunch commitment fuels our impact, are foundational to our mission of accelerating health equity, one patient at a time.

As we write this message in the final year of our Equity in Action plan, the story of 2025 is unmistakable: momentum is on our side, but the need is growing even faster. Global health funding is tightening under geopolitical pressures, even as the availability of innovative medicines has expanded dramatically, reaching into more countries than ever before but remaining inaccessible for the vast majority of patients. The growing precision and sophistication of next generation therapies is exciting, yet their rising costs and complexity continue to widen disparities across the globe.

We see both extraordinary progress and an urgent truth that cannot be ignored. Each day brings new messages from patients and families outside the scope of our current programs, who cannot access the treatment they need. Their voices make one thing abundantly clear: the gap between what is possible and what is accessible is still far too wide. Consider this email we received from India in late 2025: "I am reaching out with a plea that comes straight from my heart. My dear mother was diagnosed with lymphoma. My mother is the light of our family...our foundation...our source of unwavering strength. The doctors have given us hope, but the road to recovery is financially draining... we have exhausted all our savings. Knowing that the only thing separating her from continuous, life-saving treatment is a lack of funds is a constant, agonizing fear."

Reflecting this urgent message, we took a bold stand at the 2025 Clinton Global Initiative annual meeting in September and unveiled an ambitious goal – to significantly expand our patient reach and provide equitable cancer care access to 100,000 patients annually

by the end of 2031. As we have shown over our 25-plus year history, driving global health equity takes courage, commitment, community, and collaboration. Our future ambition is therefore intentionally bold, rooted in the conviction that those most affected must also be the ones most heard.

In closing, we want to share a line from an opinion editorial in Devex we published in February of last year: "We know that human progress comes not from hiding behind walls, but from opening doors and extending a hand to others – both in our own communities and across the world." In that spirit, we remain profoundly hopeful and resolutely believe in a future shaped by those acting with humanity, a future where every person can strive for health with dignity and hope.

Pat Garcia-Gonzalez, CEO and Co-Founder
Curt Malloy, Board Chair



2025 Global Impact

Driving health equity worldwide by accelerating access to life-extending medicines, diagnostics, and support to those who need it most

4,952

4,952 new patients received access to treatment and/or support services for the first time, a 16% increase from 2024

17

17 therapies for 15 critical diseases were delivered, increasing the number of disease areas supported

84

Our access programs covered 84 countries, 17 of which received a new treatment for the first time

40,561

40,561 patients with cancer and critical diseases received access to treatment and/or support services

58%

58% of patients benefited from program support and accompaniment services, highlighting the growing demand for support beyond medicine

11.2M

More than 11.2M daily doses of breakthrough cancer and rare disease medication were delivered

16,884

16,884 patients received support through our patient services, such as transportation support and education, a 48% increase over 2024

57

Clinical training for 57 healthcare professionals across 10 countries helped further strengthen healthcare system capacity, enhancing medical expertise and quality of care

100%

Nearly 100% of suspected adverse events to treatments were reported within 24 hours, reflecting the effectiveness of training and early commitment to patient safety

\$358.6M

\$358.6M in medicines that enabled access to treatment across 84 countries

11,475

Provided 11,475 diagnostic tests and tools across 43 countries, a 15% increase over 2024

9

Conducted 9 site capacity assessments to measure local health system capabilities and guide targeted investments to ensure that program implementation is aligned with local capacity

9

9 partnerships through our Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) strengthened our capacity to deliver essential medicines and diagnostics to patients who need them most



Meaningful Advancements in Health Equity

We reached over 40,000 patients for the first time, with an 85% patient retention year over year, reflecting our continued expansion into underserved communities and commitment to continuity of care.

All regions saw steady growth in patients reached, with Africa accounting for the largest share, 36% of 40,561 patients supported.

We provided access to treatment for 823 advanced breast cancer patients, an increase of 35%.

282 patients diagnosed with chronic lymphocytic leukemia (CLL) received treatment, a marked increase since the CLL program was introduced in 2024.

We introduced access to treatment for ALK+ anaplastic large cell lymphoma, bringing cutting-edge therapies to more patients for some of the world's most critical and rare conditions.

In two countries, Morocco and North Macedonia, our CML program moved to local treatment access through generic medications, marking a key milestone and underscoring our commitment to helping build sustainable access to medicines through local healthcare systems.

We expanded diagnostic testing to three new countries: Eswatini, Gambia, and Sierra Leone.

Partner institutions in 68 countries can now access lower cost PCR testing, free Spot On CML testing, and subsidized local testing, reinforcing the critical role of diagnostics in improving patient survival and quality of life.

Our collaborations encompassed 933 partners across the globe, including treating institutions, partner physicians, non-governmental organizations, ministries of health, and corporate partners and supporters.

We provided treatment free remission diagnostic monitoring and support for 125 CML patients across nine countries – a 98% increase from the previous year – and expanded the program to two new countries, El Salvador and Nepal.

We provided vital services to 16,884 patients, including transportation grants, educational assistance, and patient education and schooling support, marking a 48% increase over 2024.

Our thought leadership forum, Max Think Tank, grew to over 100 volunteers. Members provided valuable feedback on our evidence-generation strategy, recommending use of targeted case studies to show how improved access to medicines strengthens health systems and creates local economic impact. Projects based on these insights and other collaborations are underway.



Treat More Patients

Progress on our priorities

Each year, as we work to accelerate access to life-extending cancer medicines for some of the world's most underserved communities, we are not just moving a metric or tracking progress. We are honoring our mission to put humanity at the center of everything we do.


We marked an important first in 2025: we surpassed 40,000 patients receiving access to treatment and support services globally. Nearly 5,000 individuals were newly enrolled, and 85% of patients remained on treatment year over year, highlighting our continued growth and strong commitment to continuity of care. Notably, we expanded the availability of diagnostic tests, stepped up clinical training for in-country healthcare professionals, and significantly boosted our unique patient support services – advancements designed to improve access to care and reinforce local healthcare systems for lasting impact.

Of the 40,561 patients who gained access to treatment for cancer and other critical diseases last year, 16,884 patients benefited from our core patient support services. This 48% increase demonstrates the growing need to address quality of life challenges, which influence a patient's long-term health and wellness. Last Mile Transportation Assistance and Max Schooling enabled 1,234 patients to travel to essential medical appointments and 274 children of patients to remain in school.

An estimated 60% of global cancer cases occur in low- and middle-income countries. With the addition of ALK+ anaplastic large cell lymphoma,

our portfolio now covers 15 disease areas and 17 treatments, allowing even more patients to benefit from life-changing therapies. In the past few years, we introduced treatment access for people living with advanced breast cancer and chronic lymphocytic leukemia (CLL), and these programs continued to advance in 2025. With breast cancer one of the leading causes of cancer-related deaths for women worldwide, we are pleased to report that our patient reach increased by 35%. Our reach for CLL patients also grew by 41%.

According to a World Health Organization report, nearly two-thirds of global cancer deaths are projected to occur in low-resource countries by 2030, making early detection a priority to ensure timely and effective clinical diagnosis and care. In 2025, we expanded access to diagnostics for CML by 15%, to 11,475 tests across 43 countries, reflecting the rising demand from and the increasing capacity of our partner institutions. This past year also marked major advancements in how we harness technological innovation to better serve patients. Our enhanced diagnostic data capture – including a 205% increase in recorded CML monitoring test results – now provides a stronger foundation to optimize care by identifying gaps and allocating resources with greater precision.



Patients reached worldwide through Max Access Solutions, Social Determinants of Health programs, and the Treatment Free Remission Program



Yared from Ethiopia

Patient Perspective

Look at me now! I'm smiling because I have regained my health. Please extend my thanks to the donors for enabling me to live a normal life once again. I can't thank them enough."

Yared, a 39-year-old father of three, was diagnosed with chronic lymphocytic leukemia (CLL) in early 2024 after experiencing swelling in his neck, an enlarged spleen, and severe fatigue. He traveled to Addis Ababa, 310 miles away from his hometown, to confirm his diagnosis, relying on family to cover the cost of the required diagnostic tests. After his diagnosis, he met with his doctor, who explained to him The Max Foundation's free treatment support program. With his treatment well underway, his neck swelling and fatigue gone, Yared has returned to work and is cherishing his time with family.

Amplify Our Voice



Progress on our priorities

For patients living with cancer and other critical illnesses, having a voice in their healthcare options is not a luxury, it is a lifeline. When patients are heard, their health outcomes and quality of care improve in measurable, meaningful ways. Yet in many of the communities we serve – where healthcare disparities run deep and socioeconomic barriers are profound – this agency is out of reach. One of our core strategic priorities is to amplify patients’ challenges, insights, and humanity so they help influence decisions and shape the care that patients in resource-challenged countries receive.

In 2025, we elevated our global presence through high-impact panels, keynote presentations, and prestigious publications alongside industry leaders, influencers, and dedicated patient advocates. To cite two examples, at a high-level roundtable during the 80th United Nations General Assembly co-hosted by The Max Foundation, global health leaders examined how multi-sector partnerships can drive the long-term strengthening of health systems in low- and middle-income countries and help close the care gap for cancer and other noncommunicable diseases. In response to dramatically decreased U.S. federal funding for global health, CEO Pat Garcia-Gonzalez published an op-ed in Devex. In it, she argued that true human progress “will come not from hiding behind walls, but by opening doors and reaching out to help others both near our homes and across the world.” She urged readers to reject isolationism and instead “speak up on behalf of our shared humanity.”

Internally, our global team continues to evolve

and expand to keep pace with technological and environmental shifts. By accelerating the organization-wide use of AI and elevating regional voices through pivotal new hires, we are strengthening our reach, sharpening our impact, and positioning ourselves for sustained global influence. Our online channels remain agile and responsive, meeting audiences where they are and by how they choose to engage. With many languages spoken across our global teams, we are uniquely positioned to support diverse communities worldwide.


CEO Pat Garcia-Gonzalez was recognized as one of the “100 Influential Women in Oncology to Follow on Social Media” by OncoDaily, a distinction that underscores her thought leadership, visibility, and measurable impact on the future of equitable cancer care everywhere.

11

15 abstracts highlighting the work of Max and its partners were accepted to 11 major conferences



Major Publication



Among the 37 presentations and 15 abstracts shared externally in 2025, The Max Foundation published the peer-reviewed manuscript “Max Access Solutions: An Innovative Model to Bring Life-Saving Medicines to Low- and Middle-Income Countries” in *Blood Global Hematology*. The paper shows that simply making medicines available does not guarantee real-world patient access; persistent health system barriers continue to block equitable care. Achieving durable, patient-centered access, the authors argue, requires coordinated, multi-sector collaboration. Through Max Access Solutions, our flagship program, we deliver essential medicines directly to patients in low- and middle-income countries, partnering with their specialists and treating institutions. This groundbreaking model prioritizes individual patient needs while adapting to local regulatory requirements.



SCAN TO READ
THE MANUSCRIPT

Sustain Our Work Through Robust Partnerships


Progress on our priorities

Partnerships make the difference between access and absence, most notably in low- and middle-income countries. We had a robust year of building new and deepening our strong existing collaborations with partners. With seven pharmaceutical and two diagnostic partners, we are on track to meet our 2026 goal of engaging 10 partners within our Humanitarian Partnership for Access to Critical Treatments.

Our distribution of more than 11.2 million daily doses across 84 countries, supporting 15 diseases and 17 treatments, was made possible by the extraordinary commitment of our global and local partners. At its heart, The Max Foundation is a network of people helping people. In 2025, countless individuals working through our over 900 partnership collaborations – from physicians and NGOs to hospitals, treatment institutions, and corporate allies – drove our success.

In 2025, we formalized partnerships with eight global and local organizations, including: the Life Raft Group, International Kidney Cancer Coalition, Lungevity, CLL Advocates Network, CML Advocates Network, Partners In Health, the Thinking Pink Breast Cancer Foundation, and the American Cancer Society. Our newly signed five-year agreement with Novartis will cover expanded support for patients with chronic myeloid leukemia (CML), metastatic breast cancer, and other rare diseases. Together, these alliances strengthen our global reach and accelerate our ability to deliver truly patient-centered cancer care, laying the foundation for our bold ambition to treat 100,000 patients annually by 2031.

The Max Foundation's Think Tank composed of global partners and expert volunteers helped us generate new ideas to measure our impact, including the creation of case studies on how our program improves health systems in individual countries as well as the economic value created over time. Think Tank grew to more than 100 members and provided valuable support to multiple projects, helping our team do more with existing resources.



The Max Foundation collaborates with an extensive network of partners to advance the care of patients and strengthen health systems.



Dr. M. Gatua
Medical Oncologist, Kenyatta University, Kenya

Physician Perspective

The introduction of Max Access Solutions has been nothing short of transformative. It has provided a long-awaited bridge between life-saving innovation and the patients who need it...and has allowed me to treat patients based on clinical need, rather than socioeconomic status."

As a medical oncologist in Kenya, Dr. M. Gatua often felt powerless and frustrated. Although transformative therapies existed, their high cost made them nearly impossible to access for most of her patients, many of whom were young mothers. Through The Max Foundation and its unique patient support services, patients receive medicine free of charge, restoring hope and dignity while giving patients a renewed chance at life.



Revenue & Expenses

Revenue	
In-kind pharmaceutical contributions*	\$ 481,565,327
Contributions, grants, & sponsorships**	\$ 54,829,862
Diagnostic program revenue	\$ 449,215
Other income	\$ 64,733
Total	\$ 536,909,137
Expenses	
Program expenses	\$ 9,736,026
Program in-kind expenses	\$ 396,405,927
Management & general expenses	\$ 2,789,418
Fundraising expenses	\$ 1,007,478
Total	\$ 409,938,849

* The Organization recognizes in-kind contributions consisting of pharmaceuticals, medical devices, and related products. These goods are recorded as inventory and revenue at fair value at the time received and as a reduction to inventory and program expense when the goods are distributed. Pharmaceutical inventory is released using a specific identification method based on expiration date and is reviewed at least annually for impairment. Pharmaceutical inventory is disposed and written off as obsolete when it is determined the pharmaceutical cannot be imported into a specific country of destination with shelf-life sufficient to comply with local importation regulations and the Organization's own guidelines.

** In 2025, The Max Foundation signed a five-year collaboration agreement with a pharmaceutical partner to expand access to treatment and support services for patients living with specific cancers and rare diseases, as well as to strengthen local healthcare systems. Based on accounting principles generally accepted in the United States (U.S. GAAP), the entirety of the operational revenue from the agreement is recognized in our 2025 consolidated financials. Receipt of actual funds will occur over the five-year agreement, from January 2026 to December 2030. Without recognition of the funding from this agreement, received revenue in 2025 for contributions, grants & sponsorships was \$8,877,862.

Donors & Supporters

Humanitarian PACT Members & Supporters

ABC Global Alliance	CLL Advocates Network	International PNH Interest Group (IPIG)
American Society for Clinical Pathology	CML Advocates Network	LUNGeity
BeOne Medicines USA	Eli Lilly and Company	Novartis
BD (Becton, Dickinson, & Company)	International Kidney Cancer Coalition (IKCC)	<i>Pioneer in Treatment Access</i>
Bristol Myers Squibb	Incyte Biosciences International Sàrl	Pfizer Inc.
Cepheid	International Workshop on CLL (iwCLL)	Takeda Pharmaceuticals International
		The Life Raft Group

Humanitarian PACT is a multi-stakeholder collaboration of organizations that share our commitment to increase global access to treatment for people living with cancer and rare diseases. These vital partners invest resources and/or their unique capabilities to support our mission.

Donors

Aarthi Raju	Gregory Kalemkerian & Mary Varterasian	Oluyemi Ajayi, MD
Alan D. Smith	Isabelle Lindenmayer	Orin Levine & Amie Batson
Alicia Annamalay, PhD	JACE Foundation	Pat Garcia-Gonzalez ♦
Alireza Ali	Jason Shapiro	Patricia Keegan
Alison Roos, PhD	Jerry P. Scott & Odette Batik	Paul Aliu, PharmD
Amadou Diarra, PhD	John & Nancy Schuessler	Paula & Paul Boulton
Amanda Schwartz	John Damonti	Richard Lloyd
American University of Kuwait Model United Nations Club	Judith Saryan	Rob Keel & Anna Pradal
Andrew & Leanne Holes	Julie Jenson	Rod Padua
Andrielle Yost	Karen M. Kasprzyk	Rosanne Rotondo ♦
Anonymous (17)	Kate Thorson	SET Ventures
Aparna Anderson, PhD	Ken Kieffer ♦	Sonia de Bary Pereda
Aresa Toukdarian, PhD	Kristin Bedard	Staci & Dan Kearney
Arlene Saryan & Christian Alexander	Laura & Guy Maas	Steven Jones & Michelle Thiessen
Armenian Missionary Association of America	Lauren Cohen	Susan Hayes
Benjamin & Tinya Anderson	Lawrence N Shulman, MD & Linda Jacobs, PhD	Tanner Pharma Group
BeOne Care Foundation	Leo Selvaraj	Tatiana Nemtelea
Blueprint Medicines, a Sanofi Company	Lindsay & David Kurs	Teri Tanimura
Brian Meenaghan	Liza & Geoff Cook	Terns Pharmaceuticals, Inc. a subsidiary of Merck & Co., Inc.
Chris Pierce & Jonathan Pollock	Maria Fasulo & Laurie Olson	Terri-Ann Betancourt
Curt & Ana Malloy	Maria Pia Ruffilli, MD & Susan Silberman	Thermo Fisher Scientific
Diane Munch	Mariam Izoria, PhD ♦	Tiffany Arnone & Ted Bartlett
Edgar & Carrie Thomas	Marine Durand	Tiffany Patrick
Ellen Baker, MD	Mei Ching Ong	Toni Hoover & Alfred Nettles
Ellen Rafferty ♦	Melissa Gunn	Tracey Higgins
Emanuela Chiaranda	Michael Mandola	Vera & Murray Wilson
Emily Beedle	Michael Wrigglesworth	Viji Venkatesh
Erin Schwartz & Eric Ozretich	Mike & Sarah Hamilton	
Fausto Loberiza	Natia Kakutia ♦	
Fred Wurden	Neal Parry & Shannon Hieger ♦	
Galina Vid, PhD	Nelson de Franco	
Graciela Mabel Woloj Rothstein, PhD	Nerissa Teichroew & Mike Young	
	Nikhil Yadav	

This list includes people and corporations not in the Humanitarian PACT who gave \$250 or more in 2025. Thank you to everyone who contributed to the mission of The Max Foundation.

♦ Champions Circle: recurring donors who help us accelerate health equity every month, year round.

Think Tank Advisors

Abdelhakim Gaber, MD	Handel Roger Emery, MD	Ohene Opare-Sem, MD
Abdulaziz Abubeker Sherif, MD	Hari Menon, MD, DM	Oliver Henke, MD, PhD
Adana A. M. Llanos, PhD	Hemant Malhotra, MD	Patricia Silva, MD
Aina Anota, MD	Henry Ddungu, MD	Paul Aliu, PharmD
Alan D. Smith	HH Princess Dina Mired	Peter Haggert
Alexandru Eniu, MD, PhD	Isabelle Lindenmayer	Pramod John George
Alison Roos PhD	Jana Pelouchova	Precious Takondwa Makondi, PhD, MBBS
Amanda Schwartz	JC Gutierrez-Ramos	Rebecca Begley, PhD
Amit Upadhyay, MD	Jebasingh Joseph, MD, DM	Reena Nair, MD
Anna Schuh	Jeff Lane	Revathi Raj, MD
Arun Shahi, MD	Jimmy Karanja	Rod Padua
Bahija Gouimi	Johanna Rapanarilala, MD	Rosanne Rotondo
Blessing Ojika, MD	Julie Jenson	Runcie C.W. Chidebe
Brandon Leonard	Juliemarie Vander Burg	Sam Ellis
Carlo Nalin, PhD	Karen Meliksetyan, MD	Sara Rothschild
Cesare Medri, MD	Lawrence N Shulman, MD	Shrikanth Ravichandran
Charlotte O'Leary	Livingstone Simiyu	Silvia Castillo de Armas
Chris Korsmo	Lydie Ngolet, MD	Sintayehu Abebe Temesgen, MD
Christine Riley Miller	Mafalda Ramos de Matos, PhD	Staci Kearney
David Essayan, MD	Mai Ling Perman, MBBS	Sugeeth M. Thambi, MD, DM
Deepak Bansal, MD	Maia Thrift-Perry	Temidayo Fadelu, MD
Edward Cliff, MBBS	Manan Shah	Terri-Ann Betancourt
Ellen Rafferty	Manoj P. Menon, MD	Tiffany Patrick
Elzbieta Zawislak	Michael Mandola	Upal Basu Roy, PhD
Eric Jonasch, MD	Michael Wagner, MD	Vasile Musteata, MD, PhD
Eunice Orekha	Mohammed Shabbir Ezzi, MD	Verna Vanderpuye
Fatima Cardoso, MD	Moussa Bathily, MD	Vinay Vyas, MD, DM
Fatima Scipione	Nelson de Franco	Yangchen, MD
Fisihatsion Tadesse, MD	Nesrine Mejri, MD	
Geoffrey Nkhonjera, MD	Nirmesh Prakash	
Gladys Kaaya, MD	Ntokozo Ndlovu, MD	

Board of Directors

Amadou Diarra, PhD Former Senior Vice President of Global Policy, Advocacy, and Government Affairs at Bristol Myers Squibb	Jerald Radich, MD Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center	Paula Boulton Principal at PTB Consulting LLC
Aparna Anderson, PhD Portfolio Statistics Leader at the Gates Medical Research Institute; Member of the American Statistical Association	Graciela Mabel Woloj Rothstein, PhD Board Vice Chair, Principal at MW Consulting	Susan Jerian, MD President and Founder, ONCORD, Inc.
Curt Malloy, JD, MPH Board Chair; Senior Vice President, Strategic Operations at HDT.bio	Maria Pia Ruffilli, MD Former Senior Director International Public Affairs, Therapeutic Area Team, Team Leader at Pfizer	Steven Jones General Manager of Commercial Applications with EC2 at Amazon Web Services
	Pat Garcia-Gonzalez Chief Executive Officer	Viji Venkatesh Former Region Head of The Max Foundation for India & South Asia

Leadership Team

Bryan Murphy-Eustis Vice President, Program Strategy	Geoff Cook Vice President, Communications	Laura Parrotta Vice President of Strategic Partnerships
Catherina Scheepers Region Head for Africa	Inés García González Region Head for Latin America	Pat Garcia-Gonzalez Chief Executive Officer and Co-Founder
Edgar Thomas Chief Financial Officer and Vice President of Administration	J. Michael Wigglesworth Vice President, Program Operations	Mei Ching Ong Region Head for Asia & Eastern Europe

Global Team

Africa Aicha Betty Sow Ayanda Ntombela Catherina Scheepers Eunice Mwimba Evan Mapelu Geraldine Botha Jean Claude Mutabazi Jubril Esan Kayinfa Nicole Lucy Mwangi Mahoussi Joel Goudayi Mario Borain Maxane Kilosho Meron Hiruy Mmamolahlegi Mahopo Nicole Jordaan Perpertual Asiamah Tayamika Zalinga Phiri Tenaye Ashebir Tresor Mbuyi Vimbai Taruwedzera	Shalini Subramanian Socheatha Jim Sweta Agrawal Tamayanty Kurusamy Thao Tang Thi Thanh Wirat Sae Kuai Latin America Cristian Neves Cynthia Figueroa Guerra Inés Garcia Gonzalez Ivagna Rondón Jacqueline Montúfar Karen Chur Lyat Granati María Julia Sánchez Mariana Rubi Gonzalez Martha Rosario Molina Melisa Fazio Verónica Ayala Victoria Duhalde Headquarters Abigail Russo Alexander Laya Martinez Alicia Annamalay Andrielle Yost Angel Kaushish Anshika Tandon Bryan Murphy-Eustis Charmaine Vazquez Colin Forsyth Craig Anderson Dana Goodman David Palacios Diane Cryder Edgar Thomas Emanuela Chiaranda Emily Muirhead	Emma Kgopa-Chabangu Geoffrey Cook James Wigglesworth Jennifer Rynning Justin Craig Kelsey Bray Laura Parrotta Lauren Herzog Leslie Friday Lisa Walters Mahmoud Alballah Marine Durand Mercedes Arteaga Naghama Sabah Nicholas Schmidt Patricia Garcia-Gonzalez Phyllis O'Neal Pooja Patil Rachel McKelvey Sudha Samineni Tomara Henderson India Ashika Naik Ashok Boricha Beena Narayanan Dipesh Dudaye Julie Soundarva Jyotiy Parameshwaran Komal Surve Prasad Kothekar Priyanka Kandalgaokar Santosh Kadam Shaileja Nambiar Shireen Varghese Shrutika Kaspale Steven Mathew Urvashi Negi
--	--	---



Partnership & Collaboration

The Max Foundation’s 2025 partnership with Jamaica’s National Health Fund (NHF) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) exemplifies our access model, which aligns treatment delivery with local healthcare system realities, while prioritizing individual patient needs. It’s recommended that PNH patients be vaccinated against encapsulated bacteria before starting therapy. Our collaboration ensures that NHF serves as the central implementing partner responsible for vaccine procurement, creating an integrated access pathway that directly links vaccination to treatment initiation and ensures eligible patients can safely begin therapy. Working closely with leading hospitals and onco-hematologists, patients are now being approved and undergoing treatment, demonstrating how partnership can overcome access barriers and accelerate patient impact.

Partner Nonprofits

- ABC Global Alliance
- American Cancer Society
- American Society for Clinical Pathology
- Asociación Leucemia Mieloide de Argentina (ALMA)
- Asociación Mexicana De Leucemia y Gist A.C.
- ASOPALEU
- Celebrando La Vida
- Claudine Talon Foundation
- CLL Advocates Network
- CML Advocates Network
- CML Zimbabwe Trust
- CONAC
- Corporación Nacional Maxi-Vida
- Esperantra (Asociacion de Ayuda al Paciente con Cancer)
- Esperanza y Vida
- Ethiopia CML Patients Association
- Fred Hutchinson Cancer Research Center
- Friends of Max
- Fundación Unidos contra el Cáncer (FUNCA)
- Fundación Esperanza Nueva
- Global Washington
- Henzo Kenya
- International Kidney Cancer Coalition (IKCC)
- International CML Foundation
- International PNH Interest Group
- International Workshop on CLL (iwCLL)
- LePAF
- Life Raft Group
- LUNGevery
- Luz de Esperanza
- Max Family Society Malaysia
- MaxCare Foundation Nigeria
- Management Sciences for Health
- National Health Fund Jamaica
- Partners In Health
- Partnership for Quality Medical Donations
- PNH Global Alliance
- Thinking Pink Breast Cancer Foundation
- Touched By Max
- Union for International Cancer Control
- Un Paso Max

Partner Healthcare Institutions

- Argentina**
 - FUNDALEU
 - Hospital Centenario
 - Hospital Central
 - Hospital Nacional de Clínicas
 - Hospital Posadas
 - Hospital Ramos Mejía
 - Hospital Rossi
 - Hospital San Martín
 - Private Office: Dr. Bibiana Espina
 - Private Office: Dr. Ricardo Aguirre
 - Private Office: Dr. Victoria Welsh
 - Private Office: Dr. Virginia Guerrero
- Armenia**
 - Yeolyan Hematology and Oncology Center
- Azerbaijan**
 - National Hematology and Transfusiology Center
- Bahamas**
 - Hematology Oncology Consultants
- Belarus**
 - Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology
- Benin**
 - Centre National Hospitalier Universitaire – Hubert K. MAGA
- Bhutan**
 - Jigme Dorji Wangchuck National Referral Hospital
- Bolivia**
 - Clínica Los Olivos
 - Global Laboratorios
 - Hospital de Clínicas Universitario
 - Instituto Boliviano de Oncohematología
 - Instituto Oncologico del Oriente Boliviano
 - Private Office: Ricardo Villegas
- Brazil**
 - Centro de Hematologia e Hemoterapia – Universidade
- Burkina Faso**
 - Centre Hospitalier Universitaire Yalgado Ouedraogo
- Burundi**
 - Clinique Prince Louis Rwagasore
- Cambodia**
 - Hebron Medical Center
 - Mercy Medical Center Cambodia
- Cameroon**
 - Hopital General Yaoundé
- Central Africa Republic**
 - Service d’hématologie du Centre National de Transfusion Sanguine
- Chile**
 - Clínica Icos
 - Clínica Las Condes
 - Clínica Reñaca
 - Fundación Arturo López Pérez
 - Hospital Barros Luco
 - Hospital Base Puerto Montt
 - Hospital Clínico Universidad Católica
 - Hospital del Salvador
 - Hospital JJ Aguirre
 - Hospital La Serena
 - Hospital Naval
 - Hospital Regional de Antofagasta
 - Hospital Regional de Concepción
 - Hospital Regional de Talca
 - Hospital Regional de Temuco
 - Hospital Regional de Valdivia
 - Hospital Roberto del Río
 - Hospital San Borja Arriarán
 - Hospital San Juan de Dios
 - Hospital Sótero del Río
 - Hospital Van Buren
 - INCAN
 - Private Office: Dr. Javier Anabalón
- Cote d’Ivoire**
 - CHU de Yopougon
- Democratic Republic of Congo**
 - Centre Hospitalier Nganda
- Dominican Republic**
 - Hospital Heriberto Pieter
- East Timor**
 - Bairo Pite Clinic Lanud
- Ecuador**
 - Hospital Metropolitano
 - SOLCA Núcleo de Quito
- El Salvador**
 - Hospital Nacional El Salvador
 - Hospital Nacional Rosales
- Estonia**
 - North Estonian Medical Centre

Eswatini

Manzini Government Hospital

Ethiopia

Tikur Anbessa (Black Lion) Hospital

Fiji

Colonial War Memorial Hospital

Gabon

Institut de Cancerologie Angondje

Gambia

Edward Francis Small Teaching Hospital

Georgia

LTD M. Zodelava Clinic

Acad. Grigol Mukhadze Named Hematology and Institute of Transfusionology

Ghana

Komfo Anokye Teaching Hospital

Korle-Bu Teaching Hospital

Guatemala

Hospital General San Juan de Dios

Hospital Roosevelt

Guinea

CHU Ignace Deen Conakry/Guinee

Hôpital National Donka, CHU

Haiti

Zanmi Lasante/Hôpital Bon Sauveur de Cange

Honduras

Centro de Cancer Emma R. De Callejas

India

Ananta Medical College and Research Centre

Mahavir Cancer Sansthan

A.M.R.I Hospital

Aagam Cancer Centre

Acharya Tulsi Regional Cancer Treatment and Research

Action Cancer Hospital

Advanced Centre for Treatment, Research and Education in Cancer

AIIMS Bhubaneswar

Alexis Hospital

All India Institute of medical Science

All India Institute Of Medical Science (AIIMS)

Amala Hospital

Amrita Institute of Medical Sciences

Antia's Clinical & Haematology Lab

Apex Wellness Hospital

Apollo Cancer Institutes

Apollo Hospital (Navi Mumbai)

Apollo Hospitals (Hyderabad)

Apollo Hospitals (Madurai)

Apollo Multispecialty Hospital

Apollo Specialty Hospitals (Chennai)

Arogya Multi-Speciality Clinic

Arunodaya Medical Centre

Asirvatham Super Speciality Hospital

Aster MIMS Hospital

Ayush Haemato-Onco Clinic

Batra Hospital and Medical Research Center

Bhagwan Mahaveer Cancer Hospital & Research Centre

Bhaktivedanta Hospital & Research Institute

Bharath Hospital & Institute of Oncology

BND Onco Centre

Breach Candy Hospital & Research Centre

Cancer Care Clinic

Cancer Center of America

Cancer Institute

Cancer Research Centre

Caritas Hospital

Center of Blood Disorders

CHL-CBCC Cancer Center

CMC Medical College

Deenanath Mangeshkar Hospital

Dharamsila Cancer Hospital. And Research Center

Doctors And Doctors Plaza

Dr. Alok Modi Clinic

Dr. Manish Nema Clinic & Lab

Dr. Kamakshi Memorial Hospital

Eyesrus Ophthalmic/eye hospital

Father Muller Medical College

Fortis Balaji Hospital

Fortis Hospital, Bangalore

Fortis Hospital, Ludhiana

Fortis Memorial Research Institute

G.Kuppuswamy Naidu Memorial Hospital

Ganju Haematology Clinic and Hospital

Gauhati Medical College

Government Medical College

Gujarat Cancer & Research Institute

GVN Hospital

Haemato-Oncology Care Centre (HOCC)

Harshamitra Super Speciality Hospital

HCG Cancer Centre

HCG Cancer Centre, Jaipur

HCG Cancer Centre, Mumbai

HCG Kalyannagar

HCG Panda Curie Cancer Hospital

HealthCare Global Enterprises Ltd

Hematology & Immunology Cell

Hematology Clinic

Holy Spirit Hospital

Homi Bhabha Cancer Hospital

Hope Cancer Institute

Hyderabad Omega Hospital

Indira Gandhi Co-Operative Hospital

Indira Gandhi Institute of Medical Sciences (IGIMS)

Indo-American Cancer Institute & Research Centre

Indurkar clinic

Jaslok Hospital and Research Center

Jaypee Hospital

JIPMER

Jupiter Hospital

K R Hospital

Kailash Hospital

Kane Hospital

Kashyap Nursing Home

Kerala Institute of Medical Sciences

Kidwai Memorial Institute of Oncology

King George's Medical College

Kolkata Medical College

Kovai Medical Centre And Hospital

Krishna Hospital

Krishna Institute Medical Sciences Ltd

Kumaran Hospitals Pvt. Ltd

L N Cancer Hospital

LH Hiranandani Hospital

Lisie Hospital

Lokmanya Tilak Municipal General Hospital

Lotus Institute of Hematology and Oncology

Lourdes Hospital

Mahatma Gandhi Medical College & Hospital

Malabar Cancer Center

Manas Hospital

Manavata Cancer Centre

Mangalore Institute of Oncology

Mangalore Institute of Oncology Udupi, Day Care Centre

Manipal Hospital

Manipal Hospital Yeshwanthpur

Manipal Hospital, Comprehensive Cancer Centre

Manipal Hospital, Vijayawada

Max Super Speciality Hospital

Max Super Speciality Hospital, Ghaziabad

Mayom Hospital

Medanta Cancer Institute

Medicity Hospital

MGM's Medical College & Hospital

Microdiagnostic

Mittal Hospital

MNJ Hospital

Mohan B Agarwal Clinic



Dr. Kabelo Mputsoe
Clinical Oncologist,
Ministry of Health, Lesotho

Physician
Perspective

I am a mountain girl born in the highlands of Lesotho. I specialized in oncology in Zambia. When I came back home ... there were no files, no room for seeing patients. We were starting this department fresh. From nothing to something started – especially now with the support of The Max Foundation for our CML patients, who have been struggling to get their medicines. This is going to be a huge success for patients to have treatment at home.”

When Dr. Kabelo Mputsoe, Lesotho’s first oncologist, returned home in 2021 after completing training in Zambia, she found a stark reality: there was no infrastructure for cancer care. Patients who could afford it traveled abroad to access care. That was a turning point for Dr. Mputsoe, who has spent years building up the Senkatana Oncology Clinic in Lesotho. In 2025, The Max Foundation partnered with her and other local healthcare professionals to expand access to diagnostics, medication, and support services for chronic myeloid leukemia (CML) patients. In December 2025, with the first patient receiving treatment, Dr. Mputsoe’s dream of bringing cancer care home was finally realized.



From left: David Palacios (The Max Foundation) & Olivier Exertier (IKCC)

“Partner
Perspective

We are stronger together, and it is the combined force of our strengths that will drive global impact. At International Kidney Care Coalition (IKCC), effective collaboration is foundational to everything we do. We are confident that our partnership with The Max Foundation will meaningfully advance our mission of improving outcomes for people living with kidney cancer in low- and middle-income countries.”

Olivier Exertier
Executive Director, IKCC

Mohan Dai Oswal Cancer Hospital
MS Patel Cancer Center
Mumbai Oncocare Centre
Mumbai Oncocare Centre, Aurangabad
MVR Cancer Center and Research Institute
Naik Super Speciality Hospital
Nair Hospital
Nanavati Super Speciality Hospital
Narayana Hrudayalaya
Narayana Superspeciality Hospital
Narayani Cancer Clinic
National Cancer Institute
Netaji Subhas Chandra Bose Cancer Research Institute
Nil Ratan Sircar Medical College & Hospital (NRSMC&H)
Nizam’s Institute of Medical Sciences
NMR Curie Centre of Oncology
Omega Hospital
Oncowin Cancer Center
P. D. Hinduja Hospital and Medical Research Centre
Paras HMRI Hospital
Park Nursing Home
Patel Hospital
Patna Hematology Clinic
Post Graduate Institute of Medical Education & Research
Pragati Hospital
Prathima Cancer Hospital
Prince Aly Khan Hospital
PSRI Hospital & Research Centre
Punjab Cancer Care & Research Centre
Quality Care Hospital
Qure Hematology and Oncology Centre LLP (Dr Urmish Chudgar)
R.K. Birla Cancer & Res. Center & S.M.Medical Collage
Raheja Hospital
Rajagiri Hospital
Rajendra Institute of Medical Sciences
Rajiv Gandhi Cancer Institute & Research Ctr.
Ram Krishna Cancer Care Clinic
Ramaiah Memorial Hospital
Ravi’s American Cancer Care
Regional Cancer Centre
Renova Soumya Cancer Centre
Ruby Hall Clinic
S.C.B. Medical College and Hospital
Safdurjung Hospital
Sahyadri Speciality Hospital
Sakra World Hospital
Sancheti Hospital and Cancer Institute
Sandu Cancer Centre
Sanguine Hematooncology Clinic

Sanjay Gandhi Postgraduate Institute of Medical Sc
Sanjeevani CBCC USA Cancer Hospital
Santokba Durlabhji Memorial Hospital,
Saroj Gupta Cancer Center & Research Institute
Shatabdi Hospital
Shyam Hem-Onc Clinic
SIMS Hospital
Sir Ganga Ram Hospital
SMS Medical College and Hospital
Sparsh Hospital and Critical Care Pvt. Ltd.
Sri Aurobindo Cancer Institute of Medical Sciences
Sri Guru Ram Das Institute of Medical Sciences & Research Centre
Sri Ramachandra Medical College & Research Centre
Sri Ramakrishna Institute of Oncology Research
Srinivasan Rajalakshmi Memorial Hospital
St. John’s Medical College
Surat Oncology Centre
Sushrut Hospital & Research Centre
Taran OncoCare
Tata Medical Centre
Tata Memorial Hospital
United CIIGMA Hospital
Vadamalayan Hospitals
Vasundhara cancer clinic
Vedanta Institute of Medical Sciences
Vizag Haematology Centre
VPS Lakeshore Hospital
VS hospital
Vyas Cancer Care
Vydehi institute of Medical science and Research center
Yashoda Clinic
Yashoda Hospital
Zydus Hospitals Cancer Centre

Jamaica
Cornwall Regional Hospital
Kingston Public Hospital (NPHL)
University Hospital Of The West Indies

Kenya
Aga Khan University Hospital
Coast General Teaching & Referral Hospital
Jaramogi Oginga Odinga Teaching & Referral Hospital
Kenyatta University Teaching Referral And Research Hospital
Moi Teaching & Referral Hospital
Nakuru Level 5 Hospital
The Nairobi Hospital

Kyrgyzstan
National Oncology and Hematology Center

Laos
Mittaphab Hospital

Latvia
Riga East University Hospital

Lesotho
Senkatana Oncology Clinic

Lithuania
Vilniaus Universiteto Ligoninė Santaros Klinikos

Madagascar
Service d’Oncologie C.H.U – H.J.R.A

Malawi
College of Medicine & Queen Elizabeth Central Hospital
Kamuzu Central Hospital

Mali
Service d’hématologie oncologie médicale

Mauritius
Victoria Hospital Candos

Mexico
Hospital Angeles del Pedregal
Hospital Central de San Luis Potosí: Dr. Ignacio M
Hospital General de Mexico
Hospital General de Occidente, Secretaria de Salud
Hospital Universitario de Nuevo León: Dr. José Ele
Instituto Nacional de Cancerología (INCAN)
Instituto Nacional de Ciencias Médicas y Nutrición
Unidad de Hematología y Transfusión
Unidad de Inmuno-hematología

Moldova
Institute of Oncology

Mongolia
First Central Hospital of Mongolia

Mozambique
Hospital Central de Maputo

Namibia
Private Office Dr. Michael Alison

Nepal
B.P. Koirala Memorial Hospital
Patan Hospital
Sushil Koirala Prakhar Cancer Hospital

Nicaragua
Hospital Roberto Calderon Gutierrez

Niger

Hôpital National de Niamey

Nigeria

National Hospital, Abuja
Obafemi Awolowo University Teaching Hospitals Comp

Papua New Guinea

Nazarene Health Ministries, INC
Port Moresby General Hospital

Paraguay

Hospital de Clínicas
IPS Central I

Peru

Hospital Regional Honorio Delgado
Instituto Nacional de Enfermedades Neoplasicas

Philippines

Asian Hospital and Medical Center
BMSC Medical Imaging Center, O and E Bldg.
Cebu Doctor's Hospital
Chinese General Hospital
Chong Hua Hospital
Lung Center of the Philippines
Makati Medical Center
Medical Arts Bldg. Iloilo Mission Hospital
Medical Center Manila
National Kidney and Transplant Institute
Pediicare Clinic
Perpetual Succor Hospital
Philippine General Hospital
San Pedro Hospital of Davao City
St. Luke's Medical Center
University of Santo Tomas Hospital
Victor R. Potenciano Medical Center
ZAEC Community Medical Center San Jose
Zambales Doctors' Clinics

Republic of Congo

Centre Hospitalier et Universitaire de Brazzaville

Republic of Serbia

University Clinical Center of Serbia

Rwanda

Partners In Health / Inshuti Mu Buzima
Rwanda Military Hospital

Saint Lucia

Victoria Hospital

Senegal

Hospital Dalal Jamm

Seychelles

Seychelles Hospital

Sierra Leone

Connaught Teaching Hospital, Freetown

Solomon Islands

National Referral Hospital

Sri Lanka

National Cancer Hospital, Maharagama
Nawaloka Private Hospital
North Colombo Teaching Hospital Ragama
Oasis Hospital, Colombo
Provincial General Hospital
Teaching Hospital, Kandy

Sudan

Port Sudan Oncology Centre

Surinam

University Hospital Paramaribo, AZP

Tajikistan

National Medical Centre of the Republic of Tajikistan
(Shifobakhsh)

Tanzania

Kilimanjaro Christian Medical Center
Ocean Road Cancer Institute

Togo

Campus Teaching Hospital of Lome
CHU Sylvanus Olympio

Uganda

Joint Clinical Research Centre Limited
Mulago Hospital Uganda Cancer Institute

Uzbekistan

The Republican Specialized Scientific – Practical Medical
Center Of Hematology

Vanuatu

Vila Central Hospital

Venezuela

Banco Municipal de Sangre
Centro Médico de Caracas

Zambia

University Teaching Hospital Lusaka

Zimbabwe

Parirenyatwa Hospital



KS from India

**Patient
Perspective**

Health issues may come and go, but with determination, we can rise above them. All the best to everyone ... enjoy life as much as possible."

Living with chronic myeloid leukemia since 2008, KS has been receiving his treatment free of charge through The Max Foundation and our partners, along with supportive services like Patient Support Group meetings, where he connects with others on the same path. Throughout his 17-year treatment journey, his wife has been his unwavering source of strength, encouraging him every step of the way. With their daughter now grown, the two of them are embracing life together, traveling, exploring, and celebrating how far they have come.



Leona from Paraguay

Patient Perspective

I feel such great joy being off medication. For a long time, I held myself back from many things – I was afraid to travel, worried about not being able to carry or store my treatment properly. Now, my life feels normal again, and I am truly happy.”

Leona has enjoyed playing volleyball since childhood. Following tests for unusual fatigue, she was diagnosed with chronic myeloid leukemia. A mother of two young daughters at the time, she began treatment immediately and followed it diligently. In 2021 – 20 years since starting treatment – Leona became one of the first four patients to join our Treatment Free Remission program. For long-term, well-responding patients, this program involves living without daily medication. Now a grandmother, Leona enjoys spending time with family and friends.



CONTACT US

themaxfoundation.org

425 - 778 - 8660

1448 NW Market Street
Suite 500
Seattle, WA 98107, USA

 @themaxfoundation

 @themaxfoundation

 The Max Foundation

 @themaxfoundation.org



SCAN TO
SUBSCRIBE TO
OUR NEWSLETTER